Volume : 13, Issue : 11, November – 2026
Title:
PHARMACOLOGICAL EVALUATION OF “ANTI-DEVELOPMENT AND IN VITRO EVALUATION OF SELEGILINE TRANSDERMAL PATCHES
Authors :
R. Akhila¹, Jirra Varsha, Dyaga Vijay Kumar Reddy, Dandugula Vishnu, Bajgari Akhil Kumar, Moyari Akhila
Abstract :
The present study was aimed at the formulation and evaluation of Selegiline hydrochloride transdermal patches to provide sustained drug release and improve patient compliance by overcoming the limitations associated with conventional oral therapy. It was freely soluble in methanol and ethanol, soluble in chloroform, and slightly soluble in water and phosphate buffer (pH 7.4). The maximum absorption wavelength (λmax) was found to be 247 nm, and the calibration curve exhibited excellent linearity with an R² value of 0.999. FTIR studies confirmed the compatibility of Selegiline hydrochloride with the selected polymers, indicating the absence of significant drug–excipient interactions.Transdermal patches were prepared by the solvent casting method using HPMC and Eudragit RL100 as film-forming polymers, PEG 400 as a plasticizer, and DMSO as a permeation enhancer. The prepared patches were evaluated for physicochemical parameters, including physical appearance, weight variation, thickness, folding endurance, surface pH, moisture loss, moisture absorption, in vitro drug release, and stability.All formulations showed satisfactory physicochemical characteristics with uniform appearance, acceptable thickness, good flexibility, and surface pH values within the normal skin pH range. Among the prepared formulations, F4, containing 50 mg of Eudragit RL100, demonstrated the best overall performance, exhibiting the highest folding endurance and a maximum cumulative drug release of 98.10% over 12 hours. Accelerated stability studies of the optimized formulation carried out according to ICH guidelines showed no significant changes in physical appearance, with only a slight reduction in cumulative drug release (97.82%) after three months, indicating good stability.The findings of this study suggest that the optimized Selegiline hydrochloride transdermal patch is a promising sustained-release drug delivery system with satisfactory physicochemical properties, drug release characteristics, and stability.
Keywords: Selegiline hydrochloride, Transdermal patch, Solvent casting, Sustained drug release, FTIR, Stability studies.
Cite This Article:
Please cite this article in press R. Akhila et al., Development And In Vitro Evaluation Of Selegiline Transdermal Patches.,. Indo Am. J. P. Sci, 2026; 13(11).
REFERENCES:
1. Vyas S.P and Khar R.K. Targetted and controlled Drug Delivery Novel carrier system1st ed. CBS Publishers and distributors, New Delhi, 2002; 411- 447.
2. Chein Y.W. Transdermal drug delivery and delivery system. In, Novel drug delivery system, Vol. 50, Marcel Dekker, Inc., New york, 1992 pp.301-381.
3. Martin A, Swabrik J, Cammarara A. Physical pharmacy. 4th ed. New delhi: B.I Vaverly Pvt Ltd; 1996: 264-8.
4. R.L Cleek, A.L Bunge, “A new method for estimating dermal absorption from chemical exposure.General approach”, Pharm Res, Vol.10, 497–506, 1993.
5. Hadgraft, J., Guy, R., In; Transdermal Drug Delivery, Marcel Dekker, Inc., New York and Basel, Vol. 35, 296.
6. Misra, A.N., In; Jain, N.K., Eds., Controlled and Novel Drug Delivery, 1st ed. CBS Publishers and Distributors, New Delhi, 2002, 101-107.
7. Loyd v. allen, Jr. Nicholas G. popovich, howard C. Ansel. Pharmaceutical dosage form and drug delivery systems. 8th ed. Wolters kluwer publishers, New delhi, 2009; 298-315.
8. Ghosh, T.K., Pfister, W.R., Transdermal and Topical Drug Delivery Systems, Int. Pharm., Press, 39.
9. Berner B, John VA (February 1994). “Pharmacokinetic characterization of transdermal delivery systems”. Clinical pharmacokinetics 26 (2): 121–34. PMID 8162656.
10. Shreeraj183: Transdermal drug delivery technology revisited: recent advances.
11. Breathnach AS. An Atlas of the Ultrastructure of Human Skin. London: Churchill, 1971.
12. Hashimoto K, Gross BG, Lever WF. The ultrastructure of the skin of human embryos. II. The formation of intradermal portion of the eccrine sweat duct and of the secretory segment during the first half of embryonic life. J Invest Dermatol 1966; 46: 513–29.
13. Roberts MS, Targeted drug delivery to the skin and deeper tissues: role of physiology, solute structure and disease.Clin Exp Pharmacol Physiol 1997 Nov; 24(11):874-9.
14. Jasti BR, Abraham W, Ghosh TK. Transdermal and Topical drug delivery systems. In: Ghosh TK, Jasti BR, editors. Theory and Practice of Contemporary Pharmaceutics. 1st ed. Florida: CRC Press; 2005. p. 423-53.
15. Schaefer, H. et al. (1977) Penetration, permeation, and absorption of triamcinolone acetonide in normal and psoriatic skin. Arch. Dermatol. Res. 258, 241–249.
16. Koizumi, T. et al. (1990) Transfer of diclofenac sodium across excised guinea pig skin on high-frequency pulse iontophoresis. Chem. Pharm. Bull. 38, 1022–1023.
17. Ghosh, T.K. et al. (1996) Development of a transdermal patch of methadone: in vitro evaluation across hairless mouse and human cadaver skin. Pharm. Dev.Technol. 1, 285–291.